3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
131
Lymphoma
117
Lymphoma, Large B-Cell, Diffuse
80
Precursor Cell Lymphoblastic Leukemia-Lymphoma
55
Multiple Myeloma
50
Lymphoma, Non-Hodgkin
46
Lymphoma, Follicular
45
Leukemia
39
Hodgkin Disease
33
Lymphoma, Mantle-Cell
32
Burkitt Lymphoma
32
Lymphoma, Large-Cell, Immunoblastic
21
Lymphoma, Large-Cell, Anaplastic
20
Lymphoma, B-Cell, Marginal Zone
19
Neoplasm Metastasis
16
Leukemia, Lymphocytic, Chronic, B-Cell
16
Neoplasms, Plasma Cell
15
Neoplasms
13
Lymphoma, T-Cell, Peripheral
10
Dendritic Cell Sarcoma, Interdigitating
10
Recurrence
9
Lymphoma, B-Cell
9
Primary Myelofibrosis
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Immunoblastic Lymphadenopathy
8
Blast Crisis
7
Lymphoma, T-Cell
6
Graft vs Host Disease
6
Waldenstrom Macroglobulinemia
5
Prostate Cancer Metastatic
5
Interventions
enzalutamide
4
Abiraterone Acetate
2
radium Ra 223 dichloride
1
dactolisib
1
abiraterone
1
VT-464
1
Prednisone
1
NVP-BKM120
1
Flutamide
1
Crizotinib
1
Control Groups
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Castration-resistant Prostate Cancer
×
Prednisone
×
Clear all
NCT02429193
2020-01-13
BARRIER-P
University Health Network, Toronto
Phase 2
Completed
16 enrolled